| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Microbiology, University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands 6009, Australia
The ability of eight neutralizing monoclonal antibodies (MAbs) specific for structural proteins of murine cytomegalovirus (MCMV) to protect mice passively against MCMV infection was examined to determine firstly whether a correlation existed between the neutralization titres of the MAbs in vitro and the protection afforded by the MAbs in vivo and, secondly, the contribution of the host towards neutralization by the MAbs in vivo. The reduction in MCMV titre in the livers of BALB/c and C57BL/10 mice by the MAbs closely correlated with their neutralization titres in vitro. However, in the spleens of BALB/c mice, in which MCMV replicates to high titre, almost all of the MAbs tested were ineffective in reducing MCMV replication. Indeed, a significant increase in splenic MCMV replication was observed in mice treated 24 h prior to MCMV replication with either neutralizing MAbs or polyclonal Ig. Each of six MAbs prophylactically protected between 66 and 100% of mice from an intraperitoneal challenge with 4 LD50 MCMV regardless of their neutralization titre in vitro. The persistence of MCMV replication in the salivary gland was not prevented by either polyclonal Ig or MAbs. Despite the absolute requirement for complement for the neutralization of MCMV in vitro, both polyclonal Ig and MAb 4F9 protected A/J mice, which are deficient in the fifth component of complement, as efficiently as they did complement competent BALB/c mice. These results demonstrate that MAbs specific for single MCMV polypeptides are protective in vivo. In addition, the extent to which the MAbs protected against MCMV could not be predicted from their immunoreactive or neutralizing titres in vitro or by their effect on splenic MCMV replication in vivo. Furthermore, these studies suggest that the mechanism(s) of neutralization of MCMV in vitro are different to those which act in vivo.
Present address: Department of Pathology, Cambridge University, Tennis Court Road, Cambridge CB2 1QP, U.K.
Received 24 May 1990;
accepted 4 October 1990.
This article has been cited by other articles:
|
|
 |
|
  V. H. Nguyen, S. Shashidhar, D. S. Chang, L. Ho, N. Kambham, M. Bachmann, J. M. Brown, and R. S. Negrin The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation Blood, January 15, 2008; 111(2): 945 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Cicin-Sain, I. Bubic, M. Schnee, Z. Ruzsics, C. Mohr, S. Jonjic, and U. H. Koszinowski Targeted Deletion of Regions Rich in Immune-Evasive Genes from the Cytomegalovirus Genome as a Novel Vaccine Strategy J. Virol., December 15, 2007; 81(24): 13825 - 13834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Klenovsek, F. Weisel, A. Schneider, U. Appelt, S. Jonjic, M. Messerle, B. Bradel-Tretheway, T. H. Winkler, and M. Mach Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells Blood, November 1, 2007; 110(9): 3472 - 3479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.-J. Wils, E. Braakman, G. M. G. M. Verjans, E. J. C. Rombouts, A. E. C. Broers, H. G. M. Niesters, G. Wagemaker, F. J. T. Staal, B. Lowenberg, H. Spits, et al. Flt3 Ligand Expands Lymphoid Progenitors Prior to Recovery of Thymopoiesis and Accelerates T Cell Reconstitution after Bone Marrow Transplantation J. Immunol., March 15, 2007; 178(6): 3551 - 3557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Scallan, H. Jiang, T. Liu, S. Patarroyo-White, J. M. Sommer, S. Zhou, L. B. Couto, and G. F. Pierce Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice Blood, March 1, 2006; 107(5): 1810 - 1817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Morello, M. Ye, S. Hung, L. A. Kelley, and D. H. Spector Systemic Priming-Boosting Immunization with a Trivalent Plasmid DNA and Inactivated Murine Cytomegalovirus (MCMV) Vaccine Provides Long-Term Protection against Viral Replication following Systemic or Mucosal MCMV Challenge J. Virol., January 1, 2005; 79(1): 159 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Arber, A. BitMansour, T. E. Sparer, J. P. Higgins, E. S. Mocarski, I. L. Weissman, J. A. Shizuru, and J. M. Y. Brown Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation Blood, July 15, 2003; 102(2): 421 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Morello, M. Ye, and D. H. Spector Development of a Vaccine against Murine Cytomegalovirus (MCMV), Consisting of Plasmid DNA and Formalin-Inactivated MCMV, That Provides Long-Term, Complete Protection against Viral Replication J. Virol., April 16, 2002; 76(10): 4822 - 4835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Klein, K. Schoppel, N. Amvrossiadis, and M. Mach Strain-Specific Neutralization of Human Cytomegalovirus Isolates by Human Sera J. Virol., February 1, 1999; 73(2): 878 - 886. [Abstract] [Full Text]
|
|
|
|
|
|
M. R. MacDonald, X.-Y. Li, R. M. Stenberg, A. E. Campbell, and H. W. Virgin IV Mucosal and Parenteral Vaccination against Acute and Latent Murine Cytomegalovirus (MCMV) Infection by Using an Attenuated MCMV Mutant J. Virol., January 1, 1998; 72(1): 442 - 451. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
